<DOC>
	<DOCNO>NCT02712723</DOCNO>
	<brief_summary>The purpose study determine ribociclib combination letrozole 24 week neoadjuvant endocrine therapy increase proportion woman Pre-operative Endocrine Prognostic Index ( PEPI ) score 0 surgery compare patient treated letrozole alone therefore allow patient excellent outcome without chemotherapy .</brief_summary>
	<brief_title>Letrozole Plus Ribociclib Placebo Neo-adjuvant Therapy ER-positive , HER2-negative Early Breast Cancer</brief_title>
	<detailed_description>Subjects randomize ( 1:1:1 ) either letrozole plus placebo vs. letrozole plus continuous dose ribociclib vs. letrozole plus intermittent dosing ( 3-weeks-on/1-week-off ) ribociclib . The difference clinical , pathologic radiologic response well Pre-operative Endocrine Prognostic Index ( PEPI ) score across three treatment arm examine . Subjects also follow 5 year post-treatment determine ribociclib combination letrozole 24 week result improve 5 year Relapse Free Survival ( RFS ) compare letrozole alone .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Key Pathologically confirm invasive breast cancer core needle biopsy Female subject , age ≥ 18 year Only postmenopausal woman eligible . Performance Status : Eastern Cooperative Oncology Group ( ECOG ) score 02 Invasive breast cancer must ER+ ≥66 % cell ER Allred score 68 Invasive breast cancer must HER2 negative . Clinical Stage II III ( clinical measurement and/or breast image ) Key Subjects meeting exclusion criterion baseline exclude study participation . Current use investigational agent Inflammatory breast cancer define clinically significant erythema breast and/or document dermal lymphatic invasion ( direct skin invasion tumor peau d'orange without erythema ) An excisional biopsy breast cancer Surgical axillary staging procedure prior study entry Hormone replacement therapy type , megestrol acetate , raloxifene within four week prior first study treatment Clinical radiographic evidence metastatic disease Clinically significant , uncontrolled heart disease Herbal preparations/medications list Appendix B protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ER+ , HER2-negative breast cancer</keyword>
	<keyword>Stage II III</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Femara</keyword>
	<keyword>Ribociclib</keyword>
	<keyword>LEE011</keyword>
	<keyword>Neo-adjuvant</keyword>
</DOC>